1. Home
  2. MESO vs OPRA Comparison

MESO vs OPRA Comparison

Compare MESO & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • OPRA
  • Stock Information
  • Founded
  • MESO 2004
  • OPRA 1996
  • Country
  • MESO Australia
  • OPRA Norway
  • Employees
  • MESO N/A
  • OPRA N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • OPRA Computer Software: Prepackaged Software
  • Sector
  • MESO Health Care
  • OPRA Technology
  • Exchange
  • MESO Nasdaq
  • OPRA Nasdaq
  • Market Cap
  • MESO 1.3B
  • OPRA 1.4B
  • IPO Year
  • MESO N/A
  • OPRA 2018
  • Fundamental
  • Price
  • MESO $15.81
  • OPRA $16.04
  • Analyst Decision
  • MESO Buy
  • OPRA Strong Buy
  • Analyst Count
  • MESO 4
  • OPRA 5
  • Target Price
  • MESO $18.00
  • OPRA $24.90
  • AVG Volume (30 Days)
  • MESO 148.6K
  • OPRA 773.7K
  • Earning Date
  • MESO 09-02-2025
  • OPRA 08-19-2025
  • Dividend Yield
  • MESO N/A
  • OPRA 4.98%
  • EPS Growth
  • MESO N/A
  • OPRA N/A
  • EPS
  • MESO N/A
  • OPRA 0.90
  • Revenue
  • MESO $5,670,000.00
  • OPRA $554,721,000.00
  • Revenue This Year
  • MESO $177.23
  • OPRA $22.29
  • Revenue Next Year
  • MESO $314.04
  • OPRA $15.84
  • P/E Ratio
  • MESO N/A
  • OPRA $17.84
  • Revenue Growth
  • MESO N/A
  • OPRA 29.84
  • 52 Week Low
  • MESO $6.00
  • OPRA $12.83
  • 52 Week High
  • MESO $22.00
  • OPRA $22.50
  • Technical
  • Relative Strength Index (RSI)
  • MESO 58.97
  • OPRA 43.99
  • Support Level
  • MESO $14.68
  • OPRA $15.45
  • Resistance Level
  • MESO $16.38
  • OPRA $17.72
  • Average True Range (ATR)
  • MESO 0.44
  • OPRA 0.77
  • MACD
  • MESO -0.14
  • OPRA 0.06
  • Stochastic Oscillator
  • MESO 67.05
  • OPRA 28.51

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About OPRA Opera Limited

Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.

Share on Social Networks: